HUP0302337A2 - Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0302337A2
HUP0302337A2 HU0302337A HUP0302337A HUP0302337A2 HU P0302337 A2 HUP0302337 A2 HU P0302337A2 HU 0302337 A HU0302337 A HU 0302337A HU P0302337 A HUP0302337 A HU P0302337A HU P0302337 A2 HUP0302337 A2 HU P0302337A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
aryl
atom
heteroaryl
Prior art date
Application number
HU0302337A
Other languages
English (en)
Inventor
Mark Carl Noe
Lawrence Alan Reiter
Martin James Wythes
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0302337A2 publication Critical patent/HUP0302337A2/hu
Publication of HUP0302337A3 publication Critical patent/HUP0302337A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A találmány tárgya (I) általános képletű vegyületek és gyógyászatilagelfogadható sóik, ahol a képletben A jelentése aril- vagyheteroarilcsoport, B jelentése aril, cikloalkil-, heteroaril-,heterociklusos, aril-alkil-, cikloalkil-alkil-, heteroaril-alkil- vagyheterociklusos alkilcsoport, ahol mindegyik fenti cikloalkilcsoport ésheterociklusos csoport egy vagy két kettős kötést tartalmazhat; ahol Aés B egymástól függetlenül, bármelyik olyan gyűrűszénatomján, amelytovábbi kötést képezhet, adott esetben a következő szubsztituensekkel,lehet helyettesítve F, C1, Br, CN, OH, alkil-, perfluoralkil-,perfluoralkoxi-, alkoxi- és cikloalkil-oxicsoport; X jelentése oxigén,C=O, kénatom, SO2, S=O, NR10, -CH2O-, -OCH2-, -CH2S-, -CH2(S=O)-, -CH2SO2-, -SCH2-, -SOCH2-, -SO2CH2-, -[N(R10)]CH2-, -CH2[N(R10)]-, -[N(R10)]SO2- és -SO2 -[N(R10)]-; Y jelentése egy kötés, oxigén,kénatom, C=O, SO2, S=O, NR12, -CH2-, -CH2O-, -OCH2-, -CH2S-, -CH2(S=O)-, -CH2SO2-, -SCH2-, -(S=O)CH2-, -SO2CH2-, -[N(R12)] CH2-, -CH2[N(R12)] -, -CH2CH2-, -CH=CH-, -[N(R12)]-SO2- és -SO2[N(R12)]-; R1jelentése hidrogénatom, (R2)2n+1-(C)n- vagy cikloalkilcsoport, amely akövetkező csoportból választott szubsztituenssel lehet helyettesítve:halogénatom, alkil-, alkenil-, alkinil-, R3-, R3-O-, perfluor-alkoxi-,R3-alkil-O-, R3-(C=O)-O-, (R3)2N-(C=O)-O-, -NO2, (R3)2N-, R3-(C=O)-(NR4) -, R3-(SO2)-(NR4)-, R3O- (C=O)-(NR4)-, (R3)2-N(C=O)-(NR4) -, R3-S-, R3-(S=O)-, R3- (SO2)-, (R3)2N-(SO2)-, -CN, R3-(C=O)-, R3-O(C=O)-és (R3)2N-(C=O)-; R4 valamennyi és R3 előnyös jelentése egymástólfüggetlenül hidrogénatomot vagy 1-4 szénatomos alkilcsoportotképezhet; G előnyös jelentése aril-, heteroaril-, amid- vagyamincsoport, ahol G a B gyűrű bármely további kötés kialakításáraalkalmas gyűrűszénatomjához kapcsolódó helyettesítő, és helyzete alfahelyzettől eltérő a B gyűrű Y-hoz való kapcsolódási pontjáhozviszonyítva. Ó
HU0302337A 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use HUP0302337A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24331400P 2000-10-26 2000-10-26
PCT/IB2001/001953 WO2002034726A2 (en) 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
HUP0302337A2 true HUP0302337A2 (hu) 2003-10-28
HUP0302337A3 HUP0302337A3 (en) 2004-01-28

Family

ID=36950891

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302337A HUP0302337A3 (en) 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use

Country Status (36)

Country Link
US (2) US6706723B2 (hu)
EP (1) EP1332136A2 (hu)
JP (1) JP2004512327A (hu)
KR (1) KR20030061825A (hu)
CN (1) CN1714084A (hu)
AP (1) AP2001002319A0 (hu)
AR (1) AR035362A1 (hu)
AU (1) AU2002210800A1 (hu)
BG (1) BG107651A (hu)
BR (1) BR0114917A (hu)
CA (1) CA2425280A1 (hu)
CR (1) CR6939A (hu)
CZ (1) CZ20031069A3 (hu)
EA (1) EA200300409A1 (hu)
EC (1) ECSP034568A (hu)
EE (1) EE200300195A (hu)
GT (1) GT200100214A (hu)
HN (1) HN2001000243A (hu)
HR (1) HRP20030331A2 (hu)
HU (1) HUP0302337A3 (hu)
IL (1) IL154946A0 (hu)
IS (1) IS6749A (hu)
MA (1) MA26956A1 (hu)
MX (1) MXPA03003734A (hu)
NO (1) NO20031852L (hu)
NZ (1) NZ524774A (hu)
OA (1) OA12528A (hu)
PA (1) PA8531501A1 (hu)
PE (1) PE20020585A1 (hu)
PL (1) PL362919A1 (hu)
SK (1) SK4872003A3 (hu)
SV (1) SV2003000704A (hu)
TN (1) TNSN01150A1 (hu)
UY (1) UY26981A1 (hu)
WO (1) WO2002034726A2 (hu)
ZA (1) ZA200302192B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287110T3 (es) * 2000-04-11 2007-12-16 Sankyo Company, Limited Composicion farmaceutica estabilizada que contiene un bloqueador de calcio consistente en azelnidipina.
PL362919A1 (en) * 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
EP1368327B1 (en) 2001-02-14 2004-10-20 Warner-Lambert Company LLC Benzo thiadiazine matrix metalloproteinase inhibitors
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US7294624B2 (en) * 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
ATE304015T1 (de) 2002-04-26 2005-09-15 Pfizer Prod Inc Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
JP2005529895A (ja) * 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク Ｎ置換へテロアリールオキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
MXPA04010550A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona.
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
BR0313459A (pt) 2002-08-13 2005-06-21 Warner Lambert Co Derivados monocìclicos como inibidores de metaloproteinases de matriz
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
CN100558362C (zh) * 2004-04-01 2009-11-11 霍夫曼-拉罗奇有限公司 三氧嘧啶治疗和预防支气管炎症疾病的应用
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
EP2427438B1 (en) 2009-05-05 2016-10-12 Cambria Pharmaceuticals, Inc. Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
HUE036408T2 (hu) 2011-03-14 2018-07-30 Boehringer Ingelheim Int A leukotrién-termelés benzodioxán inhibitorai
WO2013012844A1 (en) * 2011-07-19 2013-01-24 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
EP2822942B1 (en) 2012-03-06 2017-05-10 Boehringer Ingelheim International GmbH Benzodioxanes for inhibiting leukotriene production
EA201400976A1 (ru) 2012-03-06 2015-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2014042647A1 (en) * 2012-09-14 2014-03-20 Levina Elizabeth Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2015009611A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2002504916A (ja) * 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) * 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
PL362919A1 (en) * 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Also Published As

Publication number Publication date
WO2002034726A9 (en) 2003-03-06
MA26956A1 (fr) 2004-12-20
CZ20031069A3 (cs) 2004-05-12
WO2002034726A3 (en) 2002-10-17
SV2003000704A (es) 2003-01-13
HN2001000243A (es) 2002-11-07
WO2002034726A2 (en) 2002-05-02
NO20031852D0 (no) 2003-04-24
KR20030061825A (ko) 2003-07-22
TNSN01150A1 (fr) 2005-11-10
EE200300195A (et) 2003-10-15
ECSP034568A (es) 2003-06-25
BG107651A (bg) 2003-12-31
MXPA03003734A (es) 2003-07-28
NZ524774A (en) 2004-09-24
EP1332136A2 (en) 2003-08-06
PE20020585A1 (es) 2002-07-06
HRP20030331A2 (en) 2003-06-30
NO20031852L (no) 2003-06-23
OA12528A (en) 2006-06-02
ZA200302192B (en) 2004-05-05
EA200300409A1 (ru) 2003-08-28
US20020132822A1 (en) 2002-09-19
IL154946A0 (en) 2003-10-31
HUP0302337A3 (en) 2004-01-28
SK4872003A3 (en) 2004-08-03
US6706723B2 (en) 2004-03-16
CA2425280A1 (en) 2002-05-02
PL362919A1 (en) 2004-11-02
GT200100214A (es) 2002-07-03
AP2001002319A0 (en) 2001-12-31
IS6749A (is) 2003-03-17
UY26981A1 (es) 2002-06-20
JP2004512327A (ja) 2004-04-22
AR035362A1 (es) 2004-05-12
BR0114917A (pt) 2003-07-01
AU2002210800A1 (en) 2002-05-06
PA8531501A1 (es) 2003-06-30
CN1714084A (zh) 2005-12-28
CR6939A (es) 2003-11-25
US20050107414A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
HUP0302337A2 (hu) Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
HUP0203971A2 (hu) Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300743A2 (hu) Heteroarilszármazékok és alkalmazásuk gyógyszerként
HUP0402320A2 (hu) Ariloxifenil- és arilszulfanilfenil-piperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0204283A2 (hu) (Kinolil-propil)-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0204226A2 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0301745A2 (hu) Ciklopentánindolok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása
AU2003273475A1 (en) N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy
HUP9902459A2 (hu) Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására
HUP0002353A2 (hu) IV típusú foszfodiészteráz inhibitor hatású 1-cikloalkil-1,8-naftiridin-4-on-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
DE69505968T2 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
NO972666D0 (no) Anilinderivater med nitrogenmonoksyd-synteseinhiberende aktivitet
HUP0303272A2 (hu) Metabolikus modulátorként alkalmazható melonil-CoA dekarboxiláz inhibitor azol-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0102277A2 (hu) 3-Helyzetben heterociklusos csoporttal szubsztituált benzoesavszármazékot tartalmazó herbicid készítmény előállítása és alkalmazása
ES2137512T3 (es) Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico.
HUP9801386A2 (hu) Szerotonin 5-HT4 receptor parciális agonistáiként és antagonistáiként alkalmazható indazol-karboxamid-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP0102025A2 (hu) Diaril-1,3,4-oxadiazolon-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0400154A2 (hu) Heterokondenzált benzoxazepin- és benzoxatiazepin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees